
NovaBay Pharmaceuticals (NBY) Stock Forecast & Price Target
NovaBay Pharmaceuticals (NBY) Analyst Ratings
Bulls say
NovaBay Pharmaceuticals Inc. has received a significant infusion of capital with an increased acquisition offer of $11.5 million, reflecting external validation of its business prospects. The company's revenue reached $2.4 million, which demonstrates a stable financial performance amid market expectations, although it fell slightly short of both internal estimates and consensus projections. Furthermore, despite acknowledging inherent valuation risks, there is confidence that the balance of risks and opportunities positions NovaBay favorably for future growth in the eye-care and related product sectors.
Bears say
NovaBay Pharmaceuticals Inc. reported a net loss of $2.2 million, translating to an earnings per share (EPS) of $(0.60), which significantly exceeded both internal estimates of $(0.28) and consensus expectations of $(0.30). The company faces multiple risks that could adversely impact its financial outlook, including potential failures in demonstrating safety and efficacy for its product candidates, difficulty in gaining regulatory approval, and challenges related to consumer acceptance and competition. Additionally, the lack of adjusted historical financials complicates the comparability of current results with those from previous periods, further contributing to uncertainty regarding the company’s performance.
This aggregate rating is based on analysts' research of NovaBay Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
NovaBay Pharmaceuticals (NBY) Analyst Forecast & Price Prediction
Start investing in NovaBay Pharmaceuticals (NBY)
Order type
Buy in
Order amount
Est. shares
0 shares